Following months of reported rumors that biotechnology company Amgen was looing to acquire Onyx Pharmaceuticals, the two companies have confirmed plans of the transaction. Reports say the deal was made for about $10.4 billion $9.7 billion in cash, at $125 per share. The parties expect to close the deal by the year’s fourth quarter. This will be the second move by Amgen to acquire Onyx Pharma; Oynx turned down a previous offer made earlier this year for $120 a share, a deal Oynx said undervalued the company.
Featured News
As Congress Considers a Ban On State AI Regs, California and NY Forge Ahead
Jun 19, 2025 by
CPI
Canada Watchdog Calls for Easing Foreign Investment Rules in Airline Sector
Jun 19, 2025 by
CPI
Litigation Finance Battle Heats Up in Tyson Foods Price-Fixing Case
Jun 19, 2025 by
CPI
Spain Weighs Additional Conditions on BBVA’s Hostile Bid for Sabadell
Jun 19, 2025 by
CPI
Japan’s TDK Buys SoftEye to Strengthen Smart Glasses Capabilities
Jun 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Theories of Harm
Jun 17, 2025 by
CPI
What Do We Mean by Harm to the Competitive Process?
Jun 17, 2025 by
Sean Sullivan
Is There a Better Approach to Vertical Merger Analysis?
Jun 17, 2025 by
Bob Majure & Andrew Sfekas
California’s Ill-Advised Turn Toward Europeanized Theories of Harm For Single-Firm Conduct
Jun 17, 2025 by
Geoffrey Manne, Dirk Auer & Brian Albrecht
EU Competition Policy in Support of Democracy and Sustainability: What Theories of Harm When Moving Away From the Predominance of the Consumer Welfare Paradigm?
Jun 17, 2025 by
Marios C. Iacovides